Ghasem Ahangari, MT, PhD

Associate Professor of Immunogenetics, Head Department of Medical Genetics at the National Institute of Genetic Engineering and Biotechnology (NIGEB), Teheran, Iran

  “Analysis of expression changes of dopamine receptors’ genes and their pharmacogenetic

effects on apoptosis as new perspective therapy of breast cancer”

Venue: Vienna Competence Centre, Lazarettgasse

19, Vienna IX, seminar room, 1. floor

Time: Wednesday, December 16, 2015, 02.00 pm Host: Hannes Stockinger

Centre for Pathophysiology, Infectiology and Immunology - Medical University of Vienna

CENTRE FOR PATHOPHYSIOLOGY, INFECTIOLOGY AND IMMUNOLOGY MEDICAL UNIVERSITY OF VIENNA INTERNET: WWW.MEDUNIWIEN.AC.AT/CePII

COLLOQUIUM IN PATHOPHYSIOLOGY, INFECTIOLOGY AND IMMUNOLOGY

BiosketchGhasem Ahangari

Centre for Pathophysiology, Infectiology and Immunology -Medical University of Vienna

n Ghasem Ahangari’s major research interest is the expression ofgenes upon the environmental interaction of an organism.Environmental factors disturbing the dialog between the neuro- andimmune system result in imbalance or complex disorders. Heinvestigates the interaction between the immune and theneuropsychological system in disorders such as asthma, autoimmunity,cancer in individuals who had been exposed to air pollution.Particularly, he quantified changes in gene expression ofneurotransmitter receptors on blood cells, in particular T cells. Heexpanded his research to include neuropsychological changesassociated with stress factors. As principal investigator of severalgrants he found effective changes of neurotransmitter receptors andother factors relevant to these receptors. Based on the changes ofexpression of these receptors in different diseases he targeted them viaspecific agonistic or antagonistic drugs. In addition, he successfullytreated tumor cells (lung and breast cancer) with specific drugs toinduce apoptosis.

n Publicationsn Pornour M., G. Ahangari et al, 2015. New prospective therapy of breast

cancer based on selective dopamine receptor D2 agonist andantagonist effects on MCF-7 cell line. Recent Pat Anticancer DrugDiscov. 2015;10(2):214-23

n Shikhpour M, G. Ahangari. 2013. A novel report of apoptosis in humanlung carcinoma cells using selective agonist of D2-like dopaminereceptors: a new approach for the treatment of human non-small celllung cancer. International journal of Immunopathology andPharmacology, 26, 2, 29-38

n Jafari M, G. Ahangari et al. 2013. Distorted expression of dopaminereceptor genes in systemic lupus erythematosus. Immunobiology,218,979-983